Last updated on July 2020

Safety Tolerability Pharmacokinetics and Efficacy of AMG 160 in Subjects With mCRPC


Brief description of study

A study to evaluate the safety and tolerability of AMG 160 and in combination with pembrolizumab in adult subjects with metastatic castration-resistant prostate cancer (mCRPC), and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

Detailed Study Description

This is a phase I, first-in-human study to evaluate the safety and tolerability of AMG 160; a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody construct, alone and in combination with pembrolizumab in subjects with metastatic castration-resistant prostate cancer.

Clinical Study Identifier: NCT03792841

Find a site near you

Start Over

Research Site

Duarte, CA United States
  Connect »

Research Site

Camperdown, Australia
  Connect »

Research Site

Randwick, Australia
  Connect »

Research Site

Parkville, Australia
  Connect »

Research Site

Salzburg, Austria
  Connect »

Research Site

Bruxelles, Belgium
  Connect »

Research Site

Duarte, CA United States
  Connect »

Research Site

New York, NY United States
  Connect »

Research Site

Los Angeles, CA United States
  Connect »

Research Site

Rotterdam, Netherlands
  Connect »

Research Site

Indianapolis, IN United States
  Connect »

Research Site

Villejuif Cedex, France
  Connect »

Research Site

Singapore, Singapore
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.